Jubilant Pharmova FY26 Revenue Up 14% to ₹8,280 Cr; Board Proposes ₹5 Dividend
Jubilant Pharmova reported FY26 revenue of ₹8,280 Cr, up 14% YoY, driven by CDMO Sterile Injectables. Q4 FY26 revenue increased 19% to ₹2,290 Cr. The company proposed a dividend of ₹5 per share. Investments in PET manufacturing and strategic partnerships are underway to support Vision 2030.
The results include strong revenue growth, strategic advancements in critical business segments like CDMO and Radiopharma, and a clear commitment to future growth targets (Vision 2030), all of which are material for investors.
The company reported solid revenue growth across segments, strategic progress in key business areas, and a proposed dividend, indicating positive financial performance and future outlook.
Jubilant Pharmova Limited announced its financial results for the quarter and full year ended March 31, 2026. The company reported a consolidated revenue of ₹8,280 crore for the full fiscal year, marking a 14% increase year-on-year. This growth was primarily driven by incremental revenue from the new third line in the CDMO Sterile Injectable business.
For the fourth quarter of FY26, revenue surged by 19% year-on-year to ₹2,290 crore, supported by growth across its Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, and Generics segments. EBITDA for the full year grew by 8% to ₹1,326 crore, despite a 2% year-on-year increase in Q4 EBITDA to ₹363 crore, with margins impacted by lower SPECT product production at CMO Montreal and under-absorption of costs.
Normalised Profit After Tax (PAT) for the full year increased by 7% to ₹442 crore, though it saw a marginal decrease in Q4 to ₹129 crore due to higher depreciation and interest costs. The Board of Directors has proposed a dividend of ₹5 per equity share.
The company highlighted significant progress across its business segments. In CDMO Sterile Injectables, it onboarded one of the world's largest oncology products onto its Spokane Line 3, with commercial batch production expected to commence in late FY27. The CRDMO business entered a strategic partnership with Pierre Fabre, France, to expand its European footprint. In Radiopharma, the Ruby-Fill® install base grew by 35% in FY26, and the company is investing US$50 million to expand its PET manufacturing network to nine sites in the US.
Jubilant Pharmova reaffirmed its commitment to its Vision 2030, aiming to double revenues by FY30. The company expects EBITDA margins to strengthen from the second half of FY27 onwards, following the stabilization of production at the Montreal facility.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.